✦ LIBER ✦

30 The impact of alternative dosing regimens on overall survival (OS) in the treatment of non small cell lung cancer (NSCLC) with Erlotinib

✍ Scribed by Pembroke, C.; Pembroke, T.; Vigneswaran, V.; Rowley, K.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

233The impact of overall treatment time

✍ H. Willers; F. Würschmidt; H. Bünemann; H.-P. Heilmann 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 108 KB

High dose teniposide (VM26) in the treat

📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 89 KB

Evaluating the Impact of Bevacizumab Mai

✍ Dranitsaris, George; Beegle, Nancy; Ravelo, Arliene; Kalberer, Traci; Yu, Elaine 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 430 KB

PCN12 COST EFFECTIVENESS OF ERLOTINIB IN

✍ E Orlewska; A Szczesna; M Gyldmark; M Szkultecka-Debek 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

The impact of overall treatment time on

✍ Chen, Ming; Jiang, Guo-Liang; Fu, Xiao-Long; Wang, Li-Juan; Qian, Hao; Chen, Gui 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 117 KB

PCN77 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ TE Ciuleanu; M Dediu; LN Minea; S Baculea; M Szkultecka-Debek 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB